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EVIDENCE BASED MEDICINE
Is HAS-BLED score better than CHADS2 and HEMOR2RHAGES schemes in
assessing 1 year risk of major bleed in Atrial Fibrillation Patients?
Syed Habibullah Kamran,1 Syeda Maria Muzammil,2 Ayeesha Kamran Kamal3

Why is this study important?
Suboptimal administration of oral anticoagulants in
patients with atrial fibrillation, in view of bleeding
complications, has necessitated the use of a standardized
and user-friendly stroke risk stratification method in
clinical practice. The issue of deciding on which stroke
scale provides the most prognostic information and
hence serves as a reliable neurological index is an
important one. HAS-BLED, CHADS2 and HEMOR2RHAGES
are some of the risk stratification scores which have been
serving this purpose with variable success and a review is
essential to compare their relative efficacy.
Furthermore, the anti-thrombolytic guidelines in
literature lack a fair coverage of atrial fibrillation patients
and the risk assessment scores themselves do not target
atrial fibrillation patients in particular. This study
compares the predictive power of the novel HAS-BLED
scheme with preexisting CHADS2 and HEMOR2RHAGES
score in cohort of patients with atrial fibrillations
undergoing anticoagulation.
An overview of HAS-BLED, CHADS2 and HEMOR2RHAGES)
for predicting stroke in Atrial Fibrillation patients and their
current state of evidence in literature:
HAS-BLED is an acronym for Hypertension, Abnormal
Liver/Kidney Function, Stroke history, Bleeding History/
Labile INR, Elderly (Age >65yrs), Drugs/Alcohol use.
HEMOR2RAGES is an acronym for Hepatic or Renal
disease, Ethanol abuse, Malignancy, Older age (age >75),
Reduced platelet function, Re bleeding, Anemia, Genetic
factor (CYP2C9 variant),Excessive fall risk and Stroke.
CHADS2 score includes congestive heart failure (C),
hypertension (H), age (A), diabetes mellitus (D), and a
history of stroke (S)

Who were the study participants?
The Euro Heart Survey on AF recruited 5,333 AF patients
form 182 institutes in 35 European countries. Patients, 18
years of age and older with AF documented by Holter or
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ECG within preceding year were eligible and followed for
survival and episodes of major bleeding for 1 year. Comorbid conditions like abnormal liver function (CLD
diagnosed or significantly deranged LFTs), abnormal
kidney function (chronic dialysis, transplant patients,
baseline Cr >2.00) and valvular heart diseases were
defined and noted.

What were the findings?
Of the 3,456 patients that remained after excluding loss
due to non-survival and those with valvular disorders or
surgery, 53 (1.5 %) incurred major bleeds within 1 year. In
2,242 patients discharged, 286 (12%) were discharged on
OAC and antiplatelets, 828 (24.0%) on antiplatelets alone
and 352 were not administered either. The overall cstatistic derivation cohort in population was 0.72 and
consistent with the HAS-BLED c-statistic. It is noteworthy
that HAS-BLED faired a higher predictive value where
antiplatelets therapy was administered alone (c-statistic
0.91) and where no therapy was initiated (c-statistic 0.85).
HEMOR2RHAGES score yielded an overall lower predictive
value (c statistic 0.66) compared to HAS-BLED (c statistic
0.72). Among the subgroups, HEMOR2RHAGES had a
higher predictive value (0.83) compared to HAS-BLED
(0.78) for group co administered OAC and antiplatelets.
Of the patients discharged on OAC due to CHADS2 >1,
HAS-BLED accurately predicted high risk for 4 out of 33
(12%) bleeds and overestimated risk in 34 out of 1580
(2.2%) patients in whom bleeding episode did not occur.
Of 21 patients, not on therapy, with CHADS2 >1 and
incurring stroke subsequently, 1 was accurately stratified
as high risk by HAS-BLED.

What were the conclusions?
Is the HAS-BLED scheme better than
CHADS2 and HEMOR2RHAGES?
HAS-BLED performed better in predicting bleeding
complications compared to others. User friendliness is
inherent in this short acronym with ease of all the
parameters required for calculating it, readily available.
This is particularly important in situations where
genetic data is not available to calculate
HEMOR2RHAGES score. Where HAS-BLED and
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HEMOR2RHAGES performed equally (baseline c
statistic of 0.85 vs 0.81, respectively), the less
complicated nature of HAS-BLED sure favours its use in
clinical settings. Clinical usefulness of CHADS2 and
HEMOR2RHAGES is further limited due to the
involvement of factors which predispose to both
ischaemic and haemorrhagic events.

Is HAS-BLED score better than CHADS2 and HEMOR2RHAGES schemes in assessing...

this review.
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How is the study helpful in Pakistani
Context?
We need our own measures of safety, however these are
still good guidelines
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